In total 9/13 (69.2%) patients with tMN and available molecular analysis harbored TP53 variants, suggesting TP53 gene mutations are the predominant driver of malignant myeloid transformation in this population. This evidence concerns the gene TP53 and therapy-related myeloid neoplasm.